Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Omega-3 fatty acids could delay psychosis: Omega-3 fatty acids significantly reduce the chances of at-risk children and young adults developing a full-blown psychotic disorder, according to a study in the February issue of Archives of General Psychiatry. The study found participants aged 13 to 25 years who were at risk of psychosis and who took 220 mg of fish oil daily for 12 weeks were 22.6 percent less likely to progress to full psychosis than participants who took a placebo. Of the 41 participants who took fish oil, only two - 4.9 percent - became psychotic, compared to 11 - 27.5 percent - of the 40 who took a placebo, according to the study, which continued for a year. "The finding that treatment with a natural substance may prevent or at least delay the onset of psychotic disorder gives hope that there may be alternatives to anti-psychotics for the prodromal phase," say researchers led by Paul Amminger at the Oxygen Research Center, Center for Youth Mental Health, University of Melbourne, Australia. They add that stigmatization and adverse effects - including metabolic changes, sexual dysfunction and weight gain - linked to anti-psychotics often are not acceptable to young people, which elevates the importance of the study findings. The researchers also found the omega-3 group had significantly lower syndrome scale scores - positive, negative, general and total

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts